Type 2 Angiotensin II Receptor – Drugs In Development, 2021

According to the recently published report 'Type 2 Angiotensin II Receptor – Drugs In Development, 2021'; Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

The report 'Type 2 Angiotensin II Receptor – Drugs In Development, 2021' outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

– The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

HK inno.N Corp

KinDex Pharmaceuticals Inc

MorphoSys AG

Novopyxis Inc

Vicore Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development

HK inno.N Corp

KinDex Pharmaceuticals Inc

MorphoSys AG

Novopyxis Inc

Vicore Pharma AB

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles

(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-6A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones

Featured News & Press Releases

Jun 11, 2021: Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

Apr 20, 2021: Vicore Pharma to host Key Opinion Leader webinar on C21 for the treatment of COVID-19

Mar 11, 2021: Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Feb 01, 2021: Vicore Pharma Holding: Positive data from Phase II study ATTRACT in patients with COVID-19 published online

Dec 21, 2020: Vicore Pharma: Positive results show that C21 can become an important complement to COVID-19 vaccines

Dec 15, 2020: Vicore Pharma announces last patient last visit in the mechanistic phase II study with C21 in systemic sclerosis

Dec 08, 2020: Vicore Pharma’s oral C21 provides clinical improvement in Covid-19 trial

Nov 16, 2020: Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis

Oct 01, 2020: Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial

Sep 25, 2020: Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

Aug 25, 2020: Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis

Jul 27, 2020: Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India

Jun 23, 2020: Vicore Pharma expands recruitment base for the ATTRACT study

Jun 22, 2020: Vicore Pharma's drug candidate VP01 demonstrates potential for significant benefit in severe pulmonary hypertension

May 29, 2020: LifeArc awards £ 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by HK inno.N Corp, 2021

Pipeline by KinDex Pharmaceuticals Inc, 2021

Pipeline by MorphoSys AG, 2021

Pipeline by Novopyxis Inc, 2021

Pipeline by Vicore Pharma AB, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports